Kymera

Kymera Therapeutics is a biopharmaceutical company developing oral medicines using targeted protein degradation technology to treat immunology and other diseases. The company has a pipeline of therapeutics in development, including KT-621, a first-in-class oral STAT6 degrader being evaluated for atopic dermatitis.